Login

The PRISMAP Radiolanthanides Workshop

3–5 Sept 2024
Switzerland
Europe/Zurich timezone

Contact

Contribution List

24 out of 24 displayed
Export to PDF
  1. 15. 161Tb a promising radionuclide for early TRT: absorbed doses compared to 177Lu in micrometastases, cell clusters, and single tumour cells
    Dr Elif Hindié ((CHU-Bordeaux)
  2. 21. 161Tb therapies for clinical trials-experiences
    David Schmid (PSI)
  3. 23. A regulator perspective on clinical trials using new radionuclides
    Dr Anna C. Senn (FOPH)
  4. 6. Advancing Auger electron therapy: Developing methods for high-resolution spectral characterization of radioisotopes
    Emilio Andrea Maugeri (PSI - Paul Scherrer Institut)
  5. 13. CERN-MEDICIS: Experience of mass-separation with radiolanthanides towards their clinical translation
    Dr Thierry Stora (CERN)
  6. 3. Cross-section measurements towards an optimized production of theranostic radionuclides at the Bern Medical Cyclotron
    Saverio Braccini (University of Bern)
  7. 5. Decay data: the importance and impact of metrology
    Dr Sean Collins (NPL)
  8. 17. Development of 161Tb and 153Sm based radiopharmaceuticals
    Dr Maarten Ooms (SCK-CEN)
  9. 16. Dose-response effects of the additional Auger and IC electrons of 161Tb-vs 177Lu-labelled agonists and antagonists
    Dr Michel Koole (KU Leuven)
  10. 14. Dosimetric comparison of the radiolanthanides 177Lu and 161Tb for cancer therapies with radiopharmaceuticals
    Dr Peter Bernhardt (Gothenburg University)
  11. 12. High-purity radionuclides at ISOL@MYRRHA
    Dr Lucia Popescu (SEK-CEN)
  12. 20. Hybrid hydroxypyridinone-macrocyclic chelators for coordination of lanthanide and actinide radionuclides
    Michelle Ma (School of Biomedical Engineering and Imaging Sciences, King's College London)
  13. 11. Impact-TATTOOS-Novel radionuclides production in Switzerland: A design status report
    Robert Eichler (PSI - Paul Scherrer Institut)
  14. 10. Mass separation of stable and radioactive lanthanide isotopes
    Dr Ulli Köster (ILL)
  15. 4. Nuclear data measurement of lanthanides
    Frédéric J Juget (IRA)
  16. 24. Preclinical Development of 161Tb-based Radiopharmaceuticals for Radioligand Therapy
    Dr Cristina Müller (PSI)
  17. 18. Preclinical studies of subcellular targeted 161Tb-complexes for cancer radiotheranostics
    Dr Antonio Rocha Paulo (IST-ID)
  18. 1. Production and application of radiolanthanides at TRIUMF
    Paul Schaffer (TRIUMF)
  19. 8. Production and radiochemical processing of medical radiolanthanides
    Dr Michiel Van de Voorde (SCK-CEN)
  20. 9. Production of novel medically relevant radiolanthanides at Paul Scherrer Institute
    Zeynep Talip (PSI - Paul Scherrer Institut)
  21. 19. Production of Radiolanthanides for medical applications in the USA
    Paul Ellison (University of Wisconsin Madison)
  22. 22. Radiolanthanides in the pharmaceutical regulatory framework in Europe
    Dr Clemens Decristoforo (MUI)
  23. 2. Studies of different production paths of 155Tb on Gd targets: from target manufacturing to Tb/Gd separation
    Dr Thomas Sounalet (Arronax)
  24. 7. Tb radionuclides for imaging and therapy: How far have we progressed?
    Nicholas Philip van der Meulen (PSI - Paul Scherrer Institut)